E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
Mielofibrosis Primaria (MFP) o Mielofibrosis Post-policitemia Vera o Post-trombocitemia esencial (MF post-PV/TE) |
|
E.1.1.1 | Medical condition in easily understood language |
Blood disorder that means the body produces too many mature blood cells too quickly. |
Trastorno de la sangre que significa que el cuerpo produce demasiadas células sanguíneas maduras demasiado deprisa. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028537 |
E.1.2 | Term | Myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To provide extended access to momelotinib in 3 cohorts of subjects who are currently receiving treatment with MMB and have not experienced progression of disease: - Cohort 1: Study GS-US-352-0101, subjects with PMF or post-PV/ET MF - Cohort 2: Study GS-US-352-1214, subjects with PMF or post-PV/ET MF - Cohort 3: Study GS-US-352-1154, subjects with PMF or post-PV/ET MF |
El objetivo principal de este estudio es proporcionar acceso ampliado a momelotinib en 3 cohortes de pacientes que reciben actualmente tratamiento con MMB y no han experimentado progresión de la enfermedad: - Cohorte 1: estudio GS-US-352-0101, pacientes con MFP o MF post-PV/TE. - Cohorte 2: estudio GS-US-352-1214, pacientes con MFP o MF post-PV/TE - Cohorte 3: estudio GS-US-352-1154, pacientes con MFP o MF post-PV/TE |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, or GS-US-352-1154 2) Did not discontinue treatment with MMB for any reason while enrolled in Studies GS-US-352-0101, GS-US-352-1214, or GS-US-352-1154 3) Any Grade 3 or 4 (CTCAE Version 4.03) non-hematologic toxicity in the prior study that the investigator considers related to previous MMB use must have resolved, reverted to Grade 1, or reverted to baseline within the 30 days from last MMB administration to Day 1 of this study 4) Any AE requiring MMB interruption during the prior study must have resolved, reverted to Grade 1, or reverted to baseline within the 30 days from last MMB administration to Day 1 of this study |
1)Incluido actualmente en los estudios GS-US-352-0101, GS-US-352-1214 o GS-US-352-1154. 2)No interrumpió el tratamiento con MMB por ningún motivo mientras participaba en los estudios GS-US-352-0101, GS-US-352-1214 o GS-US-352-1154. 3) Cualquier toxicidad no hematológica de grado 3 o 4 (Criterios terminológicos comunes para acontecimientos adversos [Common Terminology Criteria for Adverse Events, CTCAE], versión 4.03) en el estudio anterior, que el investigador considere relacionada con el uso previo de MMB, debe haberse resuelto, haber vuelto al grado 1 o vuelto al valor inicial en el plazo de 30 días desde la última administración de MMB hasta el día 1 de este estudio. 4) Cualquier acontecimiento adverso (AA) que requiera la interrupción de MMB durante el estudio anterior debe haberse resuelto, haber vuelto al grado 1 o vuelto al valor inicial en el plazo de 30 días desde la última administración de MMB hasta el día 1 de este estudio. |
|
E.4 | Principal exclusion criteria |
1) Known hypersensitivity to MMB, its metabolites, or formulation excipient 2) Incomplete recovery from major surgery prior to Day 1 of this study 3) Presence of ≥ Grade 3 (CTCAE Version 4.03) peripheral neuropathy |
1) Hipersensibilidad conocida a MMB, sus metabolitos o los excipientes de la formulación. 2) Recuperación incompleta de una cirugía mayor antes del día 1 de este estudio. 3) Presencia de neuropatía periférica de grado ≥3 (CTCAE, versión 4.03). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence and severity of AEs, as defined by CTCAE Version 4.03 |
Incidencia y severidad de AAs, tal y como se define en CTCAE Version 4.03 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From patient enrollment to Week 96 or Early Study Drug Discontinuation visit plus 30 days |
Desde la inclusión del paciente hasta la Semana 96 o hasta la Visita de Discontinuación temprana de Fármaco del estudio más 30 días. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 61 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Bulgaria |
Canada |
Czech Republic |
Denmark |
France |
Germany |
Hungary |
Israel |
Italy |
Korea, Republic of |
Netherlands |
Poland |
Romania |
Singapore |
Spain |
Sweden |
Taiwan |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS. End of study for a subject is after the subject has completed their Week 96 or ESDD visit plus 30 days of follow-up or date of 30 June 2020, whichever occur first. |
UVUP. El fin del estudio para un paciente es después de que el paciente haya completado su Semana 96 o la Visita de DTFE más 30 días. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |